AMAALA
11.3.2020 13:34:07 CET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of leading architectural firm Denniston as the Master Planners for The Island.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200311005396/en/
Chief Executive Officer of AMAALA, Nicholas Naples, said : “AMAALA carves a unique positioning within the global hospitality portfolio, catering to select travellers looking for innovative experiential escapes. Our ambition is to create personalised experiences, catering to the individual needs of each guest. Entrenched in the philosophies of art, wellness, and inspired by the purity of the Red Sea, we are excited to be working alongside Jean-Michel Gathy and Denniston to bring to life our vision for The Island. It is here where our guests will embark on a transformational journey and feed the soul through arts and cultural offerings, with opportunities for philanthropic art co-creation.”
Representing one of AMAALA’s trio of communities, The Island will be the tranquil home of an exclusive art community, and an Arabic botanical garden bestrewn with sculptural pieces. The Island will house masterpieces across four key design elements: a contemporary art museum and academy, a Riviera-lifestyle artists’ colony, immersive artistic experiences, and art and sculpture co-creation opportunities.
Principal Designer of Denniston, Jean-Michel Gathy , said: “The Island development will be an immersive and interactive art-inspired jewel. Its lifestyle components, its landscaping, the museums, and art installations together with the art community will transform this island into the 'Diamond of the Red Sea'.
"It will feature many different venues for permanent installations or temporary exhibitions and artistic performances. The graphic layout of its spine will be distinctive from the air and will be recognised internationally as an iconic landmark. The project features all elements programmed and reflects the areas, numbers and facilities. This is truly unique, nothing like it has ever been planned before.”
The active community of The Island will be anchored by an artists' village of working studios, artisanal shops, galleries, plus exhibition and performance facilities hosting a year-round calendar of immersive, and transformative works, representing the pillar of arts and culture.
Fully aligned with Saudi Arabia’s ambitions for the future, the development of AMAALA is being rolled out across three key phases, with completion of the destination aimed for ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005396/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom